GlassScriptPhysician profile
Marwan Boulis
NPI 1861981763
$2,138.38
in general payments reported to CMS, 2019-2025
12 companies · $580 in 2025
The $580 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $120 · 2024: $1,438 · 2025: $580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,138.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $815.05 | 2024-2025 | Inspire |
| Genzyme Corporation | $219.21 | 2023-2024 | |
| Medtronic, INC. | $192.88 | 2023-2024 | Propel, Stealthstation S8 Platform |
| Cochlear Americas | $185.42 | 2024 | Osia Osi300 Implant, Baha, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode |
| Regeneron Healthcare Solutions, INC. | $153.35 | 2024 | Dupixent |
| Stryker Corporation | $149.94 | 2025 | Audion Et Dilation System |
| Ets Wound Care LLC | $148.63 | 2025 | Mirragen Advanced Wound Matrix |
| Aerin Medical INC. | $104.69 | 2024 | |
| Integra Lifesciences Corporation | $70.08 | 2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Glaxosmithkline, LLC. | $47.72 | 2025 | Nucala |
| Acclarent, INC | $37.26 | 2024 | Acclarent Navwire |
| Hikma Pharmaceuticals USA | $14.15 | 2024 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marwan Boulis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.